Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-09
2011-08-09
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S014800, C530S300000, C530S327000, C530S344000, C530S345000, C435S069700, C435S320100, C435S252300, C536S023500
Reexamination Certificate
active
07994128
ABSTRACT:
The invention relates to an isolated, synthetic or recombinant χ-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.
REFERENCES:
patent: 5441985 (1995-08-01), Foreman
patent: 5587454 (1996-12-01), Justice et al.
patent: 5714468 (1998-02-01), Binder
patent: 6794361 (2004-09-01), Lewis et al.
patent: 7326682 (2008-02-01), Lewis et al.
patent: 7507717 (2009-03-01), Lewis et al.
patent: 7851444 (2010-12-01), Lewis et al.
patent: 2009/0088389 (2009-04-01), Lewis et al.
patent: WO 91/07980 (1991-06-01), None
patent: WO 96/14079 (1996-05-01), None
patent: WO 96/40064 (1996-12-01), None
patent: WO 97/01351 (1997-01-01), None
patent: WO 97/30997 (1997-08-01), None
patent: WO 98/02148 (1998-01-01), None
patent: WO 98/05309 (1998-02-01), None
patent: WO 98/22126 (1998-05-01), None
patent: WO 98/51668 (1998-11-01), None
patent: WO 00/44769 (2000-08-01), None
International Search Report mailed Nov. 12, 1999 in connection with PCT International Application No. PCT/AU99/00844, filed Oct. 1, 1999.
Yaksh, T.L., “Pharmacology of Spinal Adrenergic Systems Which Modulate Spinal Nociceptive Processing”,Pharmacology Biochemistry&Behavior22: 845-858 (1985).
Takano, Y. & Yaksh T.L., “Characterization of the Pharmacology of Intrathecally AdministeredAlpha-2 Agonists and Antagonists in Rats”,J. Pharmacology&Experimental Therapeutics261(2): 764-772 (1992).
Howe, J.R. & Yaksh, T.L., “Changes in Sensitivity to Intrathecal Norepinephrine and Serotonin after 6-Hydroxydoparnine (6-OHDA), 5,6-Dihydroxytryptamine (5,6-DHT) or Repeated Monoamine Administration”,J. Pharmacology&Experimental Therapeutics220(2): 311-321 (1982).
Howe, J.R., et al., “Selective Antagonism of the Antinociceptive Effect of Intrathecally AppliedAlphaAdrenergic Agonists by Intrathecal Prazosin and Intrathecal Yohimbine”,J. Pharmacology&Experimental Therapeutics224(3): 552-558 (1983).
Solomon, R.E. et al., “Pharmacological Characterization ofAlphaAdrenoceptors Involved in the Antinociceptive and Cardiovascular Effects of Intrathecally Administered Clonidine”,J. Pharmacology&Experimental Therapeutics251(1): 27-38 (1989).
Fleetwood-Walker, S.M. et al., “An α2Receptor Mediates the Selective Inhibition by Noradrenaline of Nociceptive Responses of Identified Dorsal Horn Neurones”,Brain Research334: 243-254 (1985).
Sawynok, J. et al., “Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat”,Pain82: 149-158 (1999).
Ardid, D. et al., “Comparative effects of different uptake inhibitor antidepressants in two pain tests in mice”,Fundam. Clin. Pharmacol.6: 75-82 (1992).
Kawamata, T. et al., “Analgesic effect of intrathecal desipramine on carrageenan-induced thermal hyperalgesia in the rat”,British J. of Anaesthesia83(3): 449-452 (1999).
Reimann, W. et al., “The Antinociceptive Effects of Morphine, Desipramine, and Serotonin and Their Combinations After Intrathecal Injection in the Rat”,Anesth Analg88: 141-145 (1999).
Springer, J.P. et al., “Facilitatory and Inhibitory Effects of Selective Norepinephrine Reuptake Inhibitors on Hypogastric Nerve-Evoked Urethral Contractions in the Cat: A Prominent Role of Urethral β-Adrenergic Receptors”,The Journal of Urology152:515-519 (1994).
Dinan, T.G. et al., “Assessment of Central Noradrenergic Functioning in Irritable Bowel Syndrome Using a Neuroendocrine Challenge Test”,Journal of Psychosomatic Research34(5):575-580 (1990).
Leung, D. et al., “Protease Inhibitors: Current Status and Future Prospects”,Journal of Medicinal Chemistry43(3):305-341 (2000).
O'Neill, M.J et al., “Effects of Ca2+and Na+channel inhibitors in vitro and in global cerebral ischaemia in vivo”,European Journal of Pharmacology332:121-131 (1997).
Eisenach, J.C. et al., “Cerebrospinal Fluid Norepinephrine and Acetylcholine Concentrations During Acute Pain”,Anesth Analg82:621-626 (1996).
Marban, E. et al., “Structure and function of voltage-gated sodium channels”,Journal of Physiology508(3):647-657 (1998).
Yanagawa, Y. et al., “A Novel Sodium Channel Inhibitor fromConus geographus:Purification, Structure, and Pharmacological Properties”,Biochemistry27:6256-6262 (1988).
Ryan, J. et al., “Evaluation of an enkephalin analog in men with castor oil-induced diarrhea”,Clin Pharmacol Ther39:40-42 (1986).
Penttilä, 0. et al., “Studies of Rectal Mucosal Catecholamines in Ulcerative Colitis”,Annals of Clinical Research7:32-36 (1975).
Bowersox, S.S. et al. ,“Selective N-Type Neuronal Voltage-Sensitive Calcium Channel Blocker, SNX-111, Produces Spinal Antinociception in Rat Models of Acute, Persistent and Neuropathic Pain”,Journal of Pharmacology&Experimental Therapeutics279:1243-1249 (1996).
Krames, E.S. et al., “Intrathecal D-Ala2-D-Leu5-enkephalin (DADL) Restores Analgesia in a Patient Analgetically Tolerant to Intrathecal Morphine Sulfate”,Pain24:205-209 (1986).
Takagi, H. et al. , “Analgesic effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS) in patients with chronic pain”,European Neuropsychopharmacology6:43-47 (1996).
Eisenach, J.C. et al., “Intrathecal, but Not Intravenous, Clonidine Reduces Experimental Thermal or Capsaicin-Induced Pain and Hyperalgesia in Normal Volunteers”,Anesth Analg87(3):591-596 (1998).
Dubner, R. et al., “The Neurobiology of Pain and Its Modulation”,The Clinical Journal of Pain5(Suppl. 2):S1-S6 (1989).
Dyck, P.J., “New Understanding and Treatment of Diabetic Neuropathy”,The New England Journal of Medicine326(19):1287-1288 (1992).
Atkinson, J.H. et al., “A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain”,Pain76:287-296 (1998).
Micó, J.A. et al., “Implication of β1- and β2-adrenergic receptors in the antinociceptive effect of tricyclic antidepressants”,European Neuropsychopharmacology7:139-145 (1997).
Alewood Paul F.
Lewis Richard J.
Sharp Iain A.
Kam Chih-Min
Scully , Scott, Murphy & Presser, P.C.
Xenome Limited
LandOfFree
Conotoxin peptides useful as inhibitors of neuronal amine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conotoxin peptides useful as inhibitors of neuronal amine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conotoxin peptides useful as inhibitors of neuronal amine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2726280